Author:
Wang Y,Choueiri T K,Lee J-L,Tan M-H,Rha S Y,North S A,Kollmannsberger C K,McDermott D F,Heng D Y C
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37 (10): 755–762.
2. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van PH, Paridaens R, Schoffski P, Mejean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinie V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S (2014) VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncol 53 (1): 103–112.
3. Bjarnason GA, Basappa NS, Knox J, Kollmannsberger C, Reaume N, Zalewski P, Macfarlane RJ, MacKenzie MJ, Hotte SJ, Heng DY, Soulieres D, Miller J (2013) A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. J Clin Oncol 31 (Suppl): abstr TPS4594.
4. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E (2012) Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 92 (4): 503–510.
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2): 228–247.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献